Gilead Sciences Inc (GILD) carries a ŷRobot AI score of 48 out of 100. The model's fair value estimate is $137.48, 9.1% below the last close of $151.28. The chart signal reads Bearish.
| Metric | GILD |
|---|---|
| AI score | 48 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $137.48 |
| Upside to fair value | -9.1% |
| Previous close | $151.28 |
| P/E | -56.50 |
| Price / sales | 5.96 |
| Market cap | $187.15B |
| EPS | -2.59 |
| Revenue growth | 2.9% |
| 1-year price change | 7.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates Gilead Sciences Inc (GILD) at $137.48 against a last close of $151.28, implying 9.1% downside to the model's estimate.
The chart-signal model classifies GILD as Neutral as of Sep 29, 2026, with a signal score of -0.10 on a -1 to 1 scale.
GILD scores 48 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
GILD trades at -56.5 times earnings and 6.0 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for GILD reads +1.5% at 30 days, +0.2% at 90 days, and +7.1% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
Gilead Sciences Inc's revenue growth is +2.9% and free-cash-flow growth is +2819.5% on the latest reported figures.
GILD chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.